Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma.

被引：7
|
作者：
Locke, Frederick Lundry
Ghobadi, Armin
Jacobson, Caron A.
Jacobsen, Eric D.
Miklos, David Bernard
Lekakis, Lazaros J.
Braunschweig, Ira
Oluwole, Olalekan O.
Lin, Yi
Siddiqi, Tanya
Deol, Abhinav
Reagan, Patrick Michael
Farooq, Umar
Bot, Adrian
Jiang, Yizhou
Rossi, John M.
Xue, Allen
Go, William Y.
Neelapu, Sattva Swarup
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Washington Univ, Sch Med, St Louis, MO 14263 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[5] Univ Miami Hlth Syst, Sylvester Comprehens Care Ctr, Miami, FL USA
[6] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA
[7] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[8] Mayo Clin, Rochester, MN USA
[9] City Hope Natl Med, Duarte, CA USA
[10] Wayne State Univ, Karmanos Canc Ctr, Detroit, MI USA
[11] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
[12] Univ Iowa, Iowa City, IA USA
[13] Kite, Santa Monica, CA USA
[14] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.3003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3003
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Axicabtagene ciloleucel (axi-cel) in combination with rituximab (Rtx) for the treatment (Tx) of refractory large B-cell lymphoma (R-LBCL): Outcomes of the phase 2 ZUMA-14 study.
    Strati, Paolo
    Leslie, Lori Ann
    Shiraz, Parveen
    Budde, L. Elizabeth
    Oluwole, Olalekan O.
    Ulrickson, Matthew
    Ramakrishnan, Aravind
    Sun, Jennifer
    Shen, Rhine
    Kanska, Justyna
    McCroskery, Peter
    Dong, Jinghui
    Schupp, Marco Andreas
    Xu, Hairong
    Patel, Krish
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [42] Preliminary results of earlier steroid use with axicabtagene ciloleucel (Axi-Cel) in patients with relapsed/refractory large B cell lymphoma
    Topp, M. S.
    van Meerten, T.
    Wermke, M.
    Lugtenburg, P. J.
    Minnema, M. C.
    Song, K. W.
    Thieblemont, C.
    Jiang, Y.
    Plaks, V
    Kerber, A.
    Kersten, M. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 65 - 66
  • [43] ZUMA-1 Pivotal Phase 2 Trial of Axicabtagene Ciloleucel (axi-cel, KTE-C19; Anti-CD19 CAR T Cells) in Patients (pts) with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
    Neelapu, Sattva S.
    Locke, Frederick L.
    Ghobadi, Armin
    Lekakis, Lazaros J.
    Miklos, David
    Jacobson, Caron A.
    Braunschweig, Ira
    Oluwole, Olalekan
    Siddiqi, Tanya
    Lin, Yi
    Timmerman, John
    Stiff, Patrick J.
    Flinn, Iann
    Goy, Andre
    Smith, Mitchell
    Deol, Abhinav
    Farooq, Umar
    McSweeeny, Peter
    Munoz, Javier
    Avivi, Irit
    Reagan, Patrick
    Bot, Adrian
    Rossi, John
    Navale, Lynn
    Jiang, Yizhou
    Aycock, Jeff
    Elias, Meg
    Wiezorek, Jeff
    Go, William Y.
    MOLECULAR THERAPY, 2017, 25 (05) : 333 - 333
  • [44] CLINICAL AND BIOLOGIC COVARIATES OF OUTCOMES IN ZUMA-1: A PIVOTAL TRIAL OF AXICABTAGENE CILOLEUCEL (AXI-CEL; KTE-C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON-HODGKIN LYMPHOMA (NHL)
    Locke, F. L.
    Neelapu, S. S.
    Bartlett, N. L.
    Lekakis, L. J.
    Miklos, D.
    Jacobson, C. A.
    Braunschweig, I.
    Oluwole, O.
    Siddiqi, T.
    Lin, Y.
    Timmerman, J.
    Reagan, P. M.
    Bot, A.
    Rossi, J.
    Navale, L.
    Jiang, Y.
    Aycock, J.
    Elias, M.
    Wiezorek, J.
    Go, W. Y.
    HAEMATOLOGICA, 2017, 102 : 172 - 172
  • [45] Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/ Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6)
    Oluwole, Olalekan O.
    Forcade, Edouard
    Muñoz, Javier
    de Guibert, Sophie
    Vose, Julie M.
    Bartlett, Nancy L.
    Lin, Yi
    Deol, Abhinav
    McSweeney, Peter A.
    Goy, Andre H.
    Kersten, Marie Jose
    Jacobson, Caron
    Farooq, Umar
    Minnema, Monique C.
    Thieblemont, Catherine
    Timmerman, John M.
    Stiff, Patrick
    Avivi, Irit
    Tzachanis, Dimitrios
    Kim, Jenny J.
    Zheng, Yan
    Shen, Rhine R.
    Vardhanabhuti, Saran
    Van Meerten, Tom
    BLOOD, 2021, 138
  • [46] Resource Utilization and Factors Prolonging Hospitalization for Patients with Refractory and Relapsed B-Cell Lymphoma Receiving Axicabtagene Ciloleucel (Axi-cel)
    Mian, Agrima
    Wei, Wei
    Hill, Brian T.
    Hamilton, Betty K.
    Pohlman, Brad
    Jagadeesh, Deepa
    Anwer, Faiz
    Kalaycio, Matt E.
    Dean, Robert M.
    Sobecks, Ronald M.
    Majhail, Navneet S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S44 - S45
  • [47] The Phase 3, Randomized Study of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma: ZUMA-7
    Schmitz, N.
    Oluwole, O. O.
    Bishop, M. R.
    Gisselbrecht, C.
    Gordon, L. I.
    Kersten, M. J.
    Maloney, D. G.
    Caballero, M. D.
    Kuruvilla, J.
    Song, K. W.
    Jacobson, C. A.
    Nastoupil, L. J.
    Riedell, P.
    Jiang, Y.
    Rossi, J. M.
    Lee, L.
    Cheng, P.
    Locke, F. L.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 90 - 91
  • [48] Axicabtagene Ciloleucel (Axi-Cel) versus standard-of-care therapy in patients with relapsed/refractory diffuse large B cell lymphoma: The phase 3, randomized study, ZUMA-7
    Schmitz, N.
    Oluwole, O. O.
    Bishop, M. R.
    Gisselbrecht, C.
    Gordon, L. I.
    Kersten, M. J.
    Maloney, D. G.
    Caballero, M. D.
    Kuruvilla, J.
    Song, K. W.
    Jacobson, C. A.
    Nastoupil, L. J.
    Riedell, P.
    Jiang, Y.
    Rossi, J. M.
    Lee, L.
    Cheng, P.
    Locke, F. L.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 47 - 47
  • [49] Axicabtagene Ciloleucel (Axi-Cel) versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma: ZUMA-7, A Phase 3, Randomized Study
    Oluwole, Olalekan O.
    Bishop, Michael R.
    Gisselbrecht, Christian
    Gordon, Leo I.
    Kersten, Marie Jose
    Maloney, David G.
    Schmitz, Norbert
    Dolores Caballero, Maria
    Kuruvilla, John
    Song, Kevin W.
    Jacobson, Caron A.
    Nastoupil, Loretta J.
    Riedell, Peter
    Jiang, Yizhou
    Rossi, John M.
    Lee, Lillian
    Cheng, Paul
    Locke, Frederick L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S293 - S294
  • [50] Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL)
    Neelapu, Sattva S.
    Dickinson, Michael
    Ulrickson, Matthew L.
    Oluwole, Olalekan O.
    Herrera, Alex F.
    Thieblemont, Catherine
    Ujjani, Chaitra S.
    Lin, Yi
    Riedell, Peter A.
    Kekre, Natasha
    de Vos, Sven
    Yang, Yin
    Milletti, Francesca
    Goyal, Lovely
    Kawashima, Jun
    Chavez, Julio C.
    BLOOD, 2020, 136
12345